Charles Schwab Investment Management Inc. Boosts Stock Holdings in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)

Charles Schwab Investment Management Inc. boosted its position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) by 11.1% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 346,498 shares of the company’s stock after buying an additional 34,698 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.56% of Monte Rosa Therapeutics worth $1,836,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in GLUE. Bank of New York Mellon Corp grew its stake in shares of Monte Rosa Therapeutics by 16.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 109,864 shares of the company’s stock worth $411,000 after acquiring an additional 15,845 shares during the period. Acadian Asset Management LLC increased its stake in shares of Monte Rosa Therapeutics by 77.4% in the second quarter. Acadian Asset Management LLC now owns 98,557 shares of the company’s stock worth $366,000 after purchasing an additional 43,009 shares in the last quarter. American Century Companies Inc. raised its position in shares of Monte Rosa Therapeutics by 46.0% in the second quarter. American Century Companies Inc. now owns 49,410 shares of the company’s stock valued at $185,000 after purchasing an additional 15,562 shares during the period. Meeder Asset Management Inc. purchased a new stake in shares of Monte Rosa Therapeutics during the 2nd quarter valued at approximately $38,000. Finally, Dimensional Fund Advisors LP grew its stake in Monte Rosa Therapeutics by 111.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 153,758 shares of the company’s stock valued at $575,000 after buying an additional 81,083 shares in the last quarter. 79.96% of the stock is currently owned by institutional investors.

Insider Activity at Monte Rosa Therapeutics

In other Monte Rosa Therapeutics news, major shareholder Versant Venture Capital Vi, L. sold 1,132,566 shares of the business’s stock in a transaction that occurred on Friday, September 20th. The shares were sold at an average price of $6.53, for a total value of $7,395,655.98. Following the completion of the transaction, the insider now owns 5,099,336 shares of the company’s stock, valued at $33,298,664.08. The trade was a 18.17 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 6.50% of the stock is owned by corporate insiders.

Monte Rosa Therapeutics Stock Up 1.6 %

Shares of GLUE opened at $7.68 on Tuesday. The business’s 50-day moving average price is $7.86 and its 200-day moving average price is $5.87. Monte Rosa Therapeutics, Inc. has a twelve month low of $3.21 and a twelve month high of $12.40. The stock has a market cap of $471.84 million, a PE ratio of -4.20 and a beta of 1.37.

Monte Rosa Therapeutics (NASDAQ:GLUE) last posted its earnings results on Thursday, November 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.16. The firm had revenue of $9.22 million during the quarter, compared to analysts’ expectations of $4.54 million. Analysts expect that Monte Rosa Therapeutics, Inc. will post -1.49 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Wedbush restated an “outperform” rating and set a $15.00 target price on shares of Monte Rosa Therapeutics in a research report on Thursday, November 7th.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.